Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Return on Capital Employed (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Return on Capital Employed for 15 consecutive years, with 0.66% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed fell 52.0% to 0.66% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.66% through Dec 2025, down 52.0% year-over-year, with the annual reading at 0.53% for FY2025, 39.0% down from the prior year.
  • Return on Capital Employed for Q4 2025 was 0.66% at Myriad Genetics, up from 0.76% in the prior quarter.
  • The five-year high for Return on Capital Employed was 0.12% in Q3 2022, with the low at 0.76% in Q3 2025.
  • Average Return on Capital Employed over 5 years is 0.26%, with a median of 0.18% recorded in 2021.
  • The sharpest move saw Return on Capital Employed increased 17bps in 2024, then crashed -63bps in 2025.
  • Over 5 years, Return on Capital Employed stood at 0.17% in 2021, then grew by 22bps to 0.13% in 2022, then tumbled by -97bps to 0.26% in 2023, then soared by 47bps to 0.14% in 2024, then plummeted by -379bps to 0.66% in 2025.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.66%, 0.76%, and 0.65% for Q4 2025, Q3 2025, and Q2 2025 respectively.